{"id":"revaxis","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"REVAXIS contains inactivated poliovirus antigens and toxoids of diphtheria and tetanus bacteria, which trigger adaptive immune responses without causing disease. The vaccine is administered as a booster dose to individuals who have previously received primary immunization series, restoring or maintaining protective antibody levels against these three infectious diseases.","oneSentence":"REVAXIS is a combined vaccine that provides active immunization against diphtheria, tetanus, and poliomyelitis by stimulating the immune system to produce antibodies against these three pathogens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:54.091Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Booster immunization against diphtheria, tetanus, and poliomyelitis in adolescents and adults"}]},"trialDetails":[{"nctId":"NCT05193734","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2022-02-07","conditions":"Pertussis, Vaccine-Preventable Diseases","enrollment":100},{"nctId":"NCT01323959","phase":"PHASE4","title":"Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-01","conditions":"Acellular Pertussis, Poliomyelitis, Diphtheria","enrollment":212},{"nctId":"NCT00400309","phase":"PHASE3","title":"Safety of REPEVAX® Given One Month After REVAXIS®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-06","conditions":"Healthy Adult","enrollment":500},{"nctId":"NCT00447525","phase":"PHASE3","title":"REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-02","conditions":"Diphtheria, Tetanus, Poliomyelitis","enrollment":760},{"nctId":"NCT01277705","phase":"PHASE3","title":"Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-01","conditions":"Tetanus, Diphtheria, Acellular Pertussis","enrollment":806}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"REVAXIS®","genericName":"REVAXIS®","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi-pasteur-a-sanofi-company","modality":"Biologic","firstApprovalDate":"","aiSummary":"REVAXIS is a combined vaccine that provides active immunization against diphtheria, tetanus, and poliomyelitis by stimulating the immune system to produce antibodies against these three pathogens. Used for Booster immunization against diphtheria, tetanus, and poliomyelitis in adolescents and adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}